Gene · 8767
Papers2,573
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,573
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Elevated RIPK2 Expression in Atopic Dermatitis Skin Is Associated with Mixed Th1/Th2 Cytokine Responses in CD4+ T Cells. | Int J Mol Sci | 2026 | 42794681 | PubTator, text mining | PubMed |
| Multi-omics characterization of Yao syndrome identifies three pathophysiological axes and disease-specific divergence from Blau syndrome. | Inflamm Res | 2026 | 42786248 | PubTator, text mining | PubMed |
| Targeting intracellular immune regulatory molecules for cancer immunotherapy in solid tumors. | Crit Rev Oncol Hematol | 2026 | 42732787 | PubTator, text mining | PubMed |
| Identification of Cellular Senescence-Related Hub Genes in Rheumatoid Arthritis from Bioinformatics Analysis Through Machine Learning up to Verifications in Mouse Macrophages and Tests in Patients. | Int J Mol Sci | 2026 | 42653491 | PubTator, text mining | PubMed |
| A network toxicology and machine learning approach to uncover the molecular machinery of bisphenol A-induced colorectal cancer. | Sci Rep | 2026 | 42624872 | PubTator, text mining | PubMed |
| EBER-associated promoter contacts mark accessible but transcriptionally constrained RNAPII promoter hubs in EBV-positive B cells. | Epigenetics Chromatin | 2026 | 42477823 | PubTator, text mining | PubMed |
| NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer. | Signal Transduct Target Ther | 2026 | 42476973 | PubTator, text mining | PubMed |
| The dual role of RIPK family in IBD: from cell death to therapeutic targeting. | Mol Med | 2026 | 42469615 | PubTator, text mining | PubMed |
| CSN3 promotes gastric cancer progression and is associated with immune infiltration and inflammatory signaling. | Transl Cancer Res | 2026 | 42445438 | PubTator, text mining | PubMed |
| Platelet RIP2 Limits Dense Granule Release and Thrombosis via DOCK8-Cdc42. | Arterioscler Thromb Vasc Biol | 2026 | 42273729 | PubTator, text mining | PubMed |
| Receptor-interacting protein kinases (RIPK1-RIPK4) in cardiac pathophysiology: Mechanistic signaling, disease contexts, and emerging pharmacological targets. | Pharmacol Res | 2026 | 42264058 | PubTator, text mining | PubMed |
| Structural and dynamic basis of NOD2 tandem CARD association and NOD1/2-RIP2 signaling complexes. | PLoS Comput Biol | 2026 | 42213708 | PubTator, text mining | PubMed |
| Uncovering the Targets of Pueraria Associated with Programmed Cell Death and the Construction of a Diagnostic Model in Septic Cardiomyopathy. | Biomedicines | 2026 | 42193439 | PubTator, text mining | PubMed |
| ISG15 drives cervical cancer progression by hyperactivating the NOD-like receptor signaling pathway. | Cancer Genet | 2026 | 42172712 | PubTator, text mining | PubMed |
| A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association. | Transl Oncol | 2026 | 42143470 | PubTator, text mining | PubMed |
| Cigarette smoke-induced caspase-12 nuclear translocation compromises oral mucosal defense via RIP2 and NF-κB signaling. | Int Immunopharmacol | 2026 | 42105709 | PubTator, text mining | PubMed |
| Shenfu injection ameliorates coagulopathy in sepsis-associated liver injury via dual inhibition of endothelial cell pyroptosis. | Phytomedicine | 2026 | 42044593 | PubTator, text mining | PubMed |
| Receptor-interacting protein kinase 2 (RIPK2): Structural insights, pathophysiological roles, and medicinal chemistry advances in inhibitor design. | Bioorg Chem | 2026 | 42001587 | PubTator, text mining | PubMed |
| Gene Expression Alterations Associated With Resveratrol-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Osteosarcoma Cancer Cells. | J Cell Mol Med | 2026 | 41937498 | PubTator, text mining | PubMed |
| The Chemistry and Pharmacology of the Alkaloid Barettin and Its Analogues from the Marine Sponge Geodia barretti: Progress and Perspectives. | Mar Drugs | 2026 | 41892969 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8767/papers